Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ACI-24.060 at Dose A in Study Part 1a

Preclinical

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Amyloid PlaqueRecruiting

Amyloid PlaquePreclinical

Recruiting

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Amyloid Plaque

NCT05462106

Clinical

Trials by Indication[1]

Amyloid Plaque1 trial

A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)

Recruiting·AAC Immune SA·Preclinical·NCT05462106·304 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ACI-24.060 at Dose A in Study Part 1a. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ACI-24.060 at Dose A in Study Part 1a. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AC Immune SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AAC Immune SA

Related News